Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads

Journal of Infectious Diseases

Volumn 182, Issue 4, 2000, Pages 1013-1021

  Qu, Lirong ^a   Green, Michael ^b   Webber, Steven ^b   Reyes, Jorges ^b   Ellis, Demetrius ^b   Rowe, David ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; VIRUS DNA;

ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENE; VIRUS LOAD;

ADOLESCENT; CARRIER STATE; CELL LINE; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMAN; INFANT; MALE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; TRANS-ACTIVATORS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 0033795872     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315828     Document Type: Article

References (37)

1. Herpesviridae
2. Clinical and pathological features of post transplant lymphoproliferative disorders
3. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosupression
4. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression
5. Epstein-Barr virus infections in children after transplantation of the small intestine
6. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients
7. Serial measurement of Epstein-Burr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative diseases
8. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients
9. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders
10. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients
11. Natural history of Epstein-Barr virus load in pediatric thoracic recipients with post transplant lymphoproliferative disorders and other primary EBV infections
12. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
13. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders
14. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
15. Epstein-Burr virus immortalizatlon and latency
16. Studies on leukocytes growing in continuous culture derived from normal human donors
17. Characterization of EBV carrying B cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth
18. Spontaneous outgrowth of Epstein-Barr virus positive B cells lines from circulating human B cells of different buoyant densities
19. EBV persistence in memory B cells in vivo
20. A novel form of Epstein-Barr virus latency in normal B cells in vivo
21. Epstein-barr virus latent gene expression in uncultured peripheral blood lymphocytes
22. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
23. A subpopulation of normal B cells latently infected with EBV resembles Burkitt lymphoma cells in expressing EBNA1 but not EBNA2 or LMP1
24. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation
25. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation
26. Genome rearrangements activate the EBV gene whose product disrupts latency
27. The spliced BZLFI gene of EBV transactivates an early promoter and induces the virus productive cycle
28. The switch between latency and replication of Epstein-Barr virus
29. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of the primary tumor
30. EBV gene expression in posttransplant lymphoproliferative disorders
31. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma
32. The role of viral load in the diagnosis, management and possible prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease following solid organ transplantation
33. The management of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in pediatric solid-organ transplant recipients
34. Sequence-specific DNA binding of the EBV-EBNAI to clustered sites in the plasmid maintenance region
35. EBV gene expression in an NPC-related tumor
36. Expression of Epstein-Barr virus lytically related genes in African Burkitt's lymphoma: Correlation with patient response to therapy
37. Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes